Position in VRDN
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$4,897,843
-$9,106,157 QoQ
Shares Held
250,401
-44.4% QoQ
Ownership
0.243%
of shares outstanding
% of Portfolio
2.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in VRDN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Rosalind Advisors, Inc. holds $166,757,300 across 22 Biotechnology names. VRDN ranks #13 (2.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | FENC |
Fennec Pharmaceuticals Inc.
|
2,908,201 | $17,885,436 | |
| 2 | SVRA |
Savara Inc
|
3,203,721 | $17,492,316 | |
| 3 | PCVX |
Vaxcyte, Inc.
|
290,000 | $16,851,900 | |
| 4 | EYPT |
EyePoint, Inc.
|
1,036,737 | $13,363,539 | |
| 5 | XFOR |
X4 Pharmaceuticals, Inc
|
3,214,766 | $13,276,983 | |
| 6 | VOR |
Vor Biopharma Inc.
|
700,000 | $12,488,000 | |
| 7 | MDWD |
MediWound Ltd.
|
749,054 | $12,067,259 | |
| 8 | VSTM |
Verastem, Inc.
|
2,138,475 | $11,333,917 |
All Filings in VRDN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,897,843 | 250,401 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $14,004,000 | 450,000 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $12,948,000 | 600,000 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $9,786,000 | 700,000 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $8,020,600 | 595,000 | Shares | Sole | 2025-05-14 | |
| 2024-06-30 | $3,903,000 | 300,000 | Shares | Sole | 2024-07-12 | |
| 2024-03-31 | $5,253,000 | 300,000 | Shares | Sole | 2024-04-25 | |
| 2023-12-31 | $7,848,030 | 360,332 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||